In the present study, we used MethPrimer software to predict the methylation status in the DUSP9 gene promoter and found that DUSP9 was hypermethylated in a variety of cancers, such as COAD, BLCA, BRCA, LUAD, pancreatic adenocarcinoma, et al. Furthermore, BSE analysis revealed the hypermethylation status of CpG island in the promoter of DUSP9, which further led to a significant decrease of DUSP9 expression levels in human CRC. This evidence concerns the gene DUSP9 and pancreatic adenocarcinoma.